ライフサイエンスコーパス: aortic

1 Biological "aortic age" was calculated from the baseline chronologic

2 of phospholemman phosphorylation in vitro in aortic and mesenteric vessels using wire myography and m

3 ivered valve implantation (eg, transcatheter aortic and mitral valve replacements) was further elucid

4 ulsatile phantom and adult participants with aortic and/or valvular disease who were enrolled between

5 12] is the most upregulated MMP in abdominal aortic aneurysm (AAA) and, hence, MMP-12-targeted imagin

6 Abdominal aortic aneurysm (AAA) formation is characterized by infl

7 Abdominal aortic aneurysm (AAA) is a severe aortic disease with a

8 ations, the decision to operate on abdominal aortic aneurysm (AAA) is primarily on the basis of measu

9 fluences the treatment outcomes of abdominal aortic aneurysm (AAA).

10 a significant risk factor of human abdominal aortic aneurysm (AAA).

11 with age- and sex-matched controls (1:10 for aortic aneurysm and 1:100 for aortic dissection) using t

12 The incidence rates of aortic aneurysm and dissections approach the incidence r

13 95% confidence intervals (CIs) of abdominal aortic aneurysm associated with physical activity.

14 od flow) lumen and the wall structure of the aortic aneurysm from CT angiograms (CTA) was compared ag

15 Discovery of novel biomarkers for abdominal aortic aneurysm growth (AAA) prediction.

16 idence rates and hazard ratios of developing aortic aneurysm or dissection among first-degree relativ

17 n among first-degree relatives of those with aortic aneurysm or dissection, in comparison with age- a

18 Endovascular aortic aneurysm repair (EVAR), left ventricular assist d

19 5 carotid, 21,428 lower extremity, and 5,800 aortic aneurysm repair procedures.

20 , coronary artery bypass grafting, abdominal aortic aneurysm repair, abdominal aortic aneurysm repair

21 abdominal aortic aneurysm repair, abdominal aortic aneurysm repair, total hip arthroplasty, total kn

22 sion of TFEB was measured in human and mouse aortic aneurysm samples.

23 e, and 1.93 (95% CI 1.47-2.53) for abdominal aortic aneurysm.

24 e increases the risk of developing abdominal aortic aneurysms (AAA).

25 graft devices for the treatment of abdominal aortic aneurysms (AAAs) are being increasingly used worl

26 of the most common aortic diseases, namely, aortic aneurysms and acute aortic syndromes.

27 was associated with enlargement of abdominal aortic aneurysms at 1 year, particularly in aneurysms sm

28 Traditionally, thoracic aortic aneurysms have been labeled as a degenerative dis

29 The etiology of aortic aneurysms is poorly understood, but it is associa

30 In patients with large and extra-large aortic annuli, transcatheter aortic valve replacement us

31 atomic surrogate of the distance between the aortic annulus and the His bundle.

32 Median aortic annulus area and perimeter were 617 mm(2) (591-65

33 AAs, and the remodeling of the PAAs into the aortic arch artery and its major branches.

34 hogenesis of PAAs and their derivatives, the aortic arch artery and its major branches; however, thei

35 hemodynamic waves to quantify the effect of aortic arch stiffening on transmitted pulsatility to cer

36 have measured regional stiffness within the aortic arch using pulse wave velocity (PWV) and have fou

37 In thoracoabdominal NRP opening the aortic arch vessels to atmosphere allows collateral flow

38 rain was calculated from maximum and minimum aortic area measurements repeated three times by three r

39 A patient with congenital aortic atresia and limited dialysis access options prese

40 port in place before the procedure was intra-aortic balloon pump in 14 patients (67%), Impella CP in

41 xtracorporeal membrane oxygenation and intra-aortic balloon pump in 2, and extracorporeal membrane ox

42 ion (PCI) treated with MCS (Impella or intra-aortic balloon pump).

43 r hemodynamic support as compared with intra-aortic balloon pumps (IABPs), little is known about clin

44 ntation (OHT) in patients bridged with intra-aortic balloon pumps (IABPs).

45 h extracorporeal membrane oxygenation, intra-aortic balloon pumps, and exception requests and fewer c

46 MViV using aortic balloon-expandable transcatheter heart valves is

47 rat model of hypertrophy induced by thoracic aortic banding (TAB).

48 catheter with the tip placed 2 cm below the aortic bifurcation.

49 llected information for patients treated for aortic bioprosthesis failure with isolated VIV TAVR or r

50 cement (SAVR) represent the 2 treatments for aortic bioprosthesis failure.

51 as estimated from relative signal intensity (aortic blood signal intensity was used as a reference).

52 ng decreased systolic and diastolic central (aortic) blood pressure by 4 mm Hg (95% CI: 2.8 to 5.5 mm

53 angiotensin-II (Ang-II) perfusion- and peri-aortic CaCl(2) injury-induced AAA in mice.

54 locity was 10.8 m/s, and 81.3% had abdominal aortic calcification at baseline.

55 fiber deposition also had positive impact on aortic caliber.

56 Aortic carboxypeptidase-like protein (ACLP) is a collage

57 of differential baroreceptor feedback (i.e. aortic-carotid g-gradient).

58 al SMC loss with marked increases in non-SMC aortic cell mass induced exuberant growth and dilation o

59 The presence of cytosolic DNA in aortic cells and activation of the STING pathway were ex

60 Adult mice subjected to transverse aortic constriction (TAC) developed cardiac hypertrophy

61 swim exercise protocol as well as transverse aortic constriction (TAC).

62 50% reduction) in isoproterenol-, transverse aortic constriction-, and myocardial infarction (MI)-ind

63 -in mice were subjected to chronic ascending aortic constriction.

64 d genes at baseline and 91% after transverse aortic constriction.

65 mutation were subjected to chronic ascending aortic constriction.

66 ing stent bundle deployed under a variety of aortic cross-sections.

67 ding animals underwent overload relief by an aortic debanding surgery (n=10).

68 STING signaling represent a key mechanism in aortic degeneration and that targeting STING may prevent

69 Identifying mechanisms that drive aortic degeneration is a crucial step in developing an e

70 ates of the geometric quantities alone; e.g. aortic diameter ([Formula: see text], [Formula: see text

71 ercise, aortic risk remains low when maximal aortic diameter is <50 mm.

72 /-) mice caused a significant attenuation of aortic diameter, decrease in pro-inflammatory cytokines

73 outcome, normal scores reflecting change in aortic diameter, did not differ significantly between th

74 patients with unstable AAA (n = 31) based on aortic diameter, growth rate, and eligibility for surgic

75 V=0.46+/-0.10), independent of variations in aortic diameter.

76 ir and underwent rupture repair at a smaller aortic diameter.

77 or rupture are based primarily on monitoring aortic diameter.

78 No complications related to aortic dilatation occurred in this cohort.

79 It is uncertain if the risk of aortic dilation of varying degrees aggregates within fam

80 I and AS did not seem to influence change in aortic dimensions.

81 report, for the first time, muscular mitral-aortic discontinuity in HCM.

82 ard deviation]) suspected of having thoracic aortic disease were used to evaluate the proposed recons

83 Abdominal aortic aneurysm (AAA) is a severe aortic disease with a high mortality rate in the event o

84 xpression of 14-3-3 proteins in inflammatory aortic disease, a rare human autoimmune disorder with in

85 , management and outcomes of the most common aortic diseases, namely, aortic aneurysms and acute aort

86 Aortic dissection (AD) is a life-threatening emergency.

87 Aortic dissection (AD) is the most common acute conditio

88 y had not undergone aortic surgery or had an aortic dissection before their first visit.

89 rd University since the establishment of the aortic dissection classification 50 years ago.

90 ion is close to the remaining risk of type A aortic dissection in this population, which underlines t

91 The risk of type B aortic dissection is close to the remaining risk of type

92 rent strategies to assess the future risk of aortic dissection or rupture are based primarily on moni

93 rols (1:10 for aortic aneurysm and 1:100 for aortic dissection) using the Danish nationwide administr

94 a virus infection affects susceptibility for aortic dissection, and whether this risk can be attenuat

95 who died of COVID-19 after open repair of an aortic dissection, complicated by hypoxic respiratory fa

96 athological mechanical mechanisms underlying aortic dissection.

97 Our results demonstrate a rescue of aortic elastic fiber fragmentation and disorganization a

98 cell-based inhibition studies, and NET/human aortic endothelial cell (HAEC) cocultures.

99 e synthase (NOS) expression in primary human aortic endothelial cells (pHAECs).

100 decreases neutrophil transmigration through aortic endothelial cells.

101 significant reductions in challenge-induced aortic enlargement, dissection, and rupture in both the

102 s impacting the biomechanics of the cell and aortic function.

103 cluding key issues of presence or absence of aortic growth, rate of growth, and need for surgical int

104 Future Mendelian randomisation studies of aortic haemodynamic estimates, which are swift to derive

105 illustrates how population-based cardiac and aortic imaging phenotypes can be used to better define c

106 suggest that TRPV4 antagonism can attenuate aortic inflammation and remodeling via decreased smooth

107 The difference in change in aortic inflammation from baseline to week 12 for secukin

108 her incidence of residual moderate or severe aortic insufficiency among patients with bicuspid AV (2.

109 Aortic intima expression of MAARS increases by 270-fold

110 In the aortic intima, lncRNA-MAP3K4 expression was reduced by 5

111 genetic age acceleration was associated with aortic intima-media thickness in preterm infants [1.0 um

112 peated three times by three readers at three aortic levels on three retrospectively gated axial gradi

113 structures that protrude into the embryonic aortic lumen.

114 ar characteristics and key components of the aortic microenvironment, where the first hematopoietic s

115 genes and regulatory pathways active in the aortic microenvironment.

116 d microbial suppression reversibly decreases aortic miR-204 and improves endothelial function, while

117 rospective cohort of patients with anomalous aortic origin of a CA, most have remained free of exerci

118 Intraseptal anomalous aortic origin of a coronary artery is considered a benig

119 outcomes in a prospective study of anomalous aortic origin of CA patients following a standardized al

120 , and coronary artery (p=0.002) and thoracic aortic (p<0.001) calcification scores.

121 more important in older patients with other aortic pathologies and diminished baseline cardiac funct

122 y surgical treatment modality for descending aortic pathologies, and has expanded to new patient coho

123 Infrarenal aortic placement was performed in 77% of ACs whereas sup

124 ging study, the rate of progression of total aortic plaque volume was >3-fold higher with ICIs (from

125 eart failure (HF) are apparent using a trans-aortic pressure overload (TAC) model.

126 d rupture in both the thoracic and abdominal aortic regions.

127 surgery group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%).

128 The percentage of moderate or severe aortic regurgitation (AR) was low and not statistically

129 versus 3.9%; P=0.01), and moderate or severe aortic regurgitation at 30 days (10% versus 3%; P=0.002)

130 higher rate of moderate-severe paravalvular aortic regurgitation was observed in the Evolut R/PRO gr

131 severe aortic stenosis, moderate and severe aortic regurgitation, and uncorrected coarctation of the

132 aphic findings at discharge (grade III or IV aortic regurgitation, pulmonary hypertension) identified

133 Thoracic endovascular aortic repair (TEVAR) has become the primary surgical tr

134 no benefit in cumulative stress relaxation (aortic ring +/- PVAT = 4122 +/- 176; p > 0.05 vs -PVAT).

135 ddition, VSMC stiffness (-46.6%) and ex vivo aortic ring contraction force (-40.1%) were lowered and

136 t vasorelaxation induced by acetylcholine in aortic rings and reduced NADPH oxidase activity in DOCA-

137 ls and attenuated ANP-mediated relaxation of aortic rings ex vivo.

138 er therapy and who limit strenuous exercise, aortic risk remains low when maximal aortic diameter is

139 this population, which underlines the global aortic risk.

140 ght graft most closely recapitulating native aortic root biomechanics.

141 h morphological features had higher rates of aortic root injury (p < 0.001), moderate-to-severe parav

142 deling system, clinically used valve-sparing aortic root replacement conduit configurations have comp

143 ations are clinically used for valve-sparing aortic root replacement, some specifically focused on re

144 a connective tissue disorder that results in aortic root widening and aneurysm if unmanaged.

145 stional-printed heart simulator with porcine aortic roots (n=5), the anticommissural plication, Stanf

146 linically similar between grafts and control aortic roots.

147 potonia, hyperelastic skin, hearing loss and aortic rupture.

148 Last, we show monocyte accumulation at the aortic side of leaflets of explanted aortic valves.

149 sense oligonucleotides led to a reduction in aortic sinus and en face lesion areas (47.2% or 58.8% de

150 nic gene expression in the arterial wall and aortic sinus induced by severe periodontitis.

151 ng and activity-tracing studies in the mouse aortic sinus showed that the Ahr pathway is active in mo

152 ed the risk of having thoracic and abdominal aortic sizes in the highest quartile (measured by comput

153 In vitro, knockdown of GPRC5B in human aortic SMCs resulted in increased IP-dependent cAMP prod

154 Targeting Fn-EDA in human aortic SMCs suppressed the synthetic phenotype and downr

155 t the inhibition of TRPV4 channels mitigates aortic smooth muscle cell-dependent inflammatory cytokin

156 Older patients with severe aortic stenosis (AS) are increasingly identified as havi

157 introduces a study on the classification of aortic stenosis (AS) based on cardio-mechanical signals

158 The management of patients with aortic stenosis (AS) crucially depends on accurate diagn

159 on of patients with low-gradient (LG) severe aortic stenosis (AS) despite preserved left ventricular

160 a major benefit in high-gradient (HG) severe aortic stenosis (AS), the results in low-gradient (LG, m

161 replacement (SAVR) for patients with severe aortic stenosis (AS).

162 included changes in the definition of severe aortic stenosis (AS).

163 cm(2) is a defining characteristic of severe aortic stenosis (AS).

164 role of cardiac magnetic resonance (CMR) in aortic stenosis (AS).

165 uited 102 participants to 5 groups: moderate aortic stenosis (ModAS) (n=13), SevAS, left ventricular

166 riants in ELN cause nonsyndromic supravalvar aortic stenosis (SVAS).

167 ic findings in low-risk patients with severe aortic stenosis after surgical aortic valve replacement

168 ess TAVI in patients with symptomatic severe aortic stenosis at low operative risk have set the stage

169 R) on kidney function stage in patients with aortic stenosis remains poorly understood.

170 In patients with severe aortic stenosis undergoing TAVR, even with baseline impa

171 sfunction (DD) and outcomes in patients with aortic stenosis undergoing transcatheter aortic valve re

172 A total of 8107 ESRD-HD patients with aortic stenosis were included, 4130 (50%) underwent TAVR

173 105 consecutive patients with cirrhosis and aortic stenosis who underwent TAVR (n = 55) or SAVR (n =

174 with end-stage lung disease and significant aortic stenosis who were successfully bridged to lung tr

175 of an increased dilatation rate were severe aortic stenosis, moderate and severe aortic regurgitatio

176 In patients with symptomatic severe aortic stenosis, TAVI has now been explored across the e

177 a risk factor for cardiovascular disease and aortic stenosis.

178 of disease severity even in patients with HG aortic stenosis.

179 to low-risk patients with symptomatic severe aortic stenosis.

180 ive study of renal function before and after aortic stent-graft treatment was performed.

181 Our findings indicate that faster rates of aortic stiffening in mid-to-late life were associated wi

182 Aortic stiffness increases with age and is a robust pred

183 Aortic stiffness is closely linked with cardiovascular d

184 nt of alterations in angiotensin II-mediated aortic stiffness.

185 Although COV was lower when measuring aortic strain at DDA compared with AA, variability was a

186 Aortic strain variability was lowest at the level of the

187 Aortic strain was calculated from maximum and minimum ao

188 Differences in cardiac and aortic structure and function are associated with cardio

189 re included, provided they had not undergone aortic surgery or had an aortic dissection before their

190 diseases, namely, aortic aneurysms and acute aortic syndromes.

191 al Sphygmocor XCEL) (n = 5) revealed central aortic systolic pulse (CASP) and central augmentation in

192 Leuko-Rapa, flow cytometry of disaggregated aortic tissue revealed fewer proliferating macrophages i

193 scrutinized a large human RNA-Seq dataset of aortic tissue to assess the co-expression of TLR4, MD2,

194 Cells extracted from aortic tissue were analyzed and categorized with single-

195 ified 11 major cell types in human ascending aortic tissue; the high-resolution reclustering of these

196 vation of the STING pathway were examined in aortic tissues from patients with sporadic ascending tho

197 l serum concentrations of cholesterol, their aortic tissues were found to have elevated concentration

198 Transcatheter mitral valve replacement using aortic transcatheter heart valves has recently become an

199 (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII A [PARTNERII A]; NCT01

200 01314313; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII

201 ine in the PARTNER 2 trial (The Placement of Aortic Transcatheter Valves) and registry the outcomes a

202 ts of long-term doxycycline treatment on the aortic ultrastructure and skin dermis of MFS mice throug

203 d progression of calcium volume score in the aortic valve (14% [95% CI, 5-24] versus 98% [95% CI, 77-

204 Patients with bicuspid aortic valve (AV) stenosis were excluded from the pivota

205 a common form of heart disease involving the aortic valve (AV).

206 Bicuspid aortic valve (BAV) is the most prevalent congenital hear

207 3 and Evolut R/PRO implantation in bicuspid aortic valve anatomy; a higher rate of moderate-severe p

208 rlson score. EE more frequently involved the aortic valve and prosthesis (64.3% vs. 46.7%; p < 0.001;

209 atients (50.4% men; mean age, 77 years) with aortic valve area <1.3 cm(2) and analyzed the occurrence

210 Aortic valve area (AVA) <=1.0 cm(2) is a defining charac

211 Aortic valve area measurements were submitted to genome-

212 sease, causes a progressive narrowing of the aortic valve as a consequence of thickening and calcific

213 ssions Database, we identified patients with aortic valve disease admitted 2012 to 2016 for SAVR, TAV

214 ltiple links between the polygenic score for aortic valve disease and key health-related comorbiditie

215 ndle branch block may also develop following aortic valve disease or cardiac procedures.

216 ons of HF (including ischemic heart disease, aortic valve disease, atrial fibrillation, congenital he

217 ation to investigate the genetic etiology of aortic valve disease, perform clinical prediction, and u

218 ly increased in patients with more than mild aortic valve dysfunction but was independent from BAV le

219 Transcatheter aortic valve implantation (TAVI) still presents complica

220 er Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry retrospecti

221 d Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).

222 onal and phenotypic changes occurring in the aortic valve interstitial cells (VICs) during osteogenic

223 The aortic valve is an important determinant of cardiovascul

224 Aortic valve leaflet fusion pattern and sex were not ass

225 uence of thickening and calcification of the aortic valve leaflets.

226 Rates of procedural secondary outcomes (eg, aortic valve reintervention, pacemaker rates) were more

227 A strategy of initial aortic valve repair followed by delayed Ross procedure m

228 noninferior and may be superior to surgical aortic valve replacement (SAVR) for mortality, stroke, a

229 rged as a reasonable alternative to surgical aortic valve replacement (SAVR) for patients with severe

230 s with severe aortic stenosis after surgical aortic valve replacement (SAVR) or transcatheter aortic

231 c valve replacement (TAVR) and redo surgical aortic valve replacement (SAVR) represent the 2 treatmen

232 Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) and redo surgical aortic

233 ular assist device (LVAD), and transcatheter aortic valve replacement (TAVR) are expensive cardiovasc

234 conduction disturbances after transcatheter aortic valve replacement (TAVR) has been elusive.

235 Transcatheter aortic valve replacement (TAVR) has emerged as a reasona

236 The role of transcatheter aortic valve replacement (TAVR) in this high-risk popula

237 ical trial results showed that transcatheter aortic valve replacement (TAVR) is noninferior and may b

238 The effect of transcatheter aortic valve replacement (TAVR) on kidney function stage

239 aging 30 days and 1 year after transcatheter aortic valve replacement (TAVR) or surgery.

240 d expanding the indication for transcatheter aortic valve replacement (TAVR) to low-risk patients wit

241 Transcatheter aortic valve replacement (TAVR) use is increasing in pat

242 ith aortic stenosis undergoing transcatheter aortic valve replacement (TAVR).

243 hospitalizations 1 year after transcatheter aortic valve replacement (TAVR).

244 ic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).

245 HF) readmission is common post-transcatheter aortic valve replacement (TAVR).

246 omes or results in futility of transcatheter aortic valve replacement (TAVR).

247 itis may affect patients after transcatheter aortic valve replacement (TAVR).

248 cute kidney injury early after transcatheter aortic valve replacement and is an independent predictor

249 an indication for transfemoral transcatheter aortic valve replacement as agreed by the heart team wer

250 ll, 34 893 patients undergoing transcatheter aortic valve replacement at 445 hospitals were analyzed.

251 ions were commonly reported in transcatheter aortic valve replacement clinical trials.

252 evaluated patients undergoing transcatheter aortic valve replacement from November 1, 2011 to June 3

253 on individual end points after transcatheter aortic valve replacement has been conducted to date.

254 nd SURTAVI trials (Surgical or Transcatheter Aortic Valve Replacement in Intermediate-Risk Patients)

255 Although aortic valve replacement is associated with a major bene

256 eter Valves) and registry the outcomes after aortic valve replacement of the 4 flow-gradient groups.

257 and extra-large aortic annuli, transcatheter aortic valve replacement using 29-mm Sapien-3 and 34-mm

258 patients with severe symptomatic AS awaiting aortic valve replacement, there has been a trend of incr

259 consisted of a total of 22 876 referrals for aortic valve replacement, with (N=8098) TAVR and (N=14 7

260 cohort of patients undergoing transcatheter aortic valve replacement.

261 bridged to lung transplant via transcatheter aortic valve replacement.

262 d cell (RBC) transfusion after transcatheter aortic valve replacement.

263 lung transplant 56 days after transcatheter aortic valve replacement.

264 he use of CT-FFR for coronary evaluation pre-aortic valve replacement.

265 ed patients after transfemoral transcatheter aortic valve replacement; propensity score-matching iden

266 Aortic valve stenosis (AVS), which is the most common va

267 (OR, 1.04 [95% CI, 0.77-1.39]; P=0.810), and aortic valve stenosis (OR, 1.03 [95% CI, 0.56-1.90]; P=0

268 cluding subjects with a medical diagnosis of aortic valve stenosis (remaining n=308 683 individuals),

269 x was associated with causal risk ratios for aortic valve stenosis and replacement, respectively, of

270 ss index is causally associated with risk of aortic valve stenosis and replacement.

271 s causally associated with increased risk of aortic valve stenosis.

272 itral (2.18; 95% CI, 1.71-2.77) and mitral + aortic valve surgery (1.85; 95% CI, 1.33-2.58) and lowes

273 ndary Ross procedure performed after initial aortic valve surgery achieves superior long-term surviva

274 tion, or a secondary operation after initial aortic valve surgery.

275 xpanding intra-annular Portico transcatheter aortic valve system (Abbott Structural Heart, St Paul, M

276 individuals with Marfan syndrome or bicuspid aortic valve, a family history of AD was associated with

277 nd thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not

278 n reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known.

279 nt thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.

280 idomic consequences of rs174547 in tricuspid aortic valves from patients with AS.

281 and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional c

282 For patients with severely impacted aortic valves that require replacement, catheter-based b

283 t n-3 PUFA incorporation into human stenotic aortic valves was higher in noncalcified regions compare

284 c analyses were performed in human tricuspid aortic valves.

285 erogenesis, is upregulated in human calcific aortic valves.

286 at the aortic side of leaflets of explanted aortic valves.

287 al to determine the effect of ustekinumab on aortic vascular inflammation (AVI) measured by imaging,

288 Secukinumab exhibited a neutral impact on aortic vascular inflammation and biomarkers of cardiomet

289 additionally participate in altering ex vivo aortic vessel function.

290 mortality, irrespective of their total open aortic volume.

291 palmitate-induced senescence versus healthy aortic VSMCs.

292 of the cellular composition of the ascending aortic wall and reveals how the gene expression landscap

293 ze the cellular composition of the ascending aortic wall and to identify molecular alterations in eac

294 se the medial properties and function of the aortic wall by enhanced proteolytic and phagocytic activ

295 ase in MMP-2 and MMP-9 expression within the aortic wall in doxycycline-treated MFS mice.

296 mer levels in aneurysm patients with altered aortic wall integrity.

297 mocytoma), which variously lead to increased aortic wall stress.

298 aorta, calcification and ossification of the aortic wall, and inflammation, resulting in aneurysm dev

299 scle cells (SMCs) in the medial layer of the aortic wall.

300 nses by immune cells resident in the intimal aortic wall.